Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $7 from $6 and keeps a Buy rating on the shares. Paysign’s 261% year-over-year pharma growth was greater-than-expected and the company “remains in the early innings of an earnings inflection driven by pharma’s rapid program growth,” the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS: